Roche enters $1.15 billion licensing deal for Sarepta gene therapy
FILE PHOTO: The logo of Swiss drugmaker Roche is seen at its headquarters in Basel, Switzerland February 1, 2018. REUTERS/Arnd…
Sarepta shares surge after surprise approval of Duchenne Muscular Dystrophy drug
(Reuters) – Shares of Sarepta Therapeutics Inc (SRPT.O) soared 36% on Friday after U.S. regulators shocked Wall Street by approving…
U.S. FDA gives early approval to Sarepta’s newest DMD treatment
FILE PHOTO: The headquarters of the U.S. Food and Drug Administration (FDA) is seen in Silver Spring, Maryland November 4,…
FDA declines to approve Sarepta’s second Duchenne treatment
(Reuters) – Sarepta Therapeutics Inc said on Monday the U.S. Food and Drug Administration declined to approve its newest treatment…
Sarepta says adverse event report for DMD gene therapy erroneously submitted
(Reuters) – Sarepta Therapeutics Inc said on Thursday it was informed that an adverse event report was erroneously submitted to…